What is the difference between CagriSema and Semaglutide?

CagriSema: CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study. Semaglutide: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It is FDA-approved under the brand names Ozempic (diabetes) and Wegovy (weight loss) and has become one of the most widely discussed peptides in mainstream health conversations. Both are in the GLP-1 & Metabolic category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take CagriSema and Semaglutide together?

There is no specific, well-documented interaction rule for combining CagriSema and Semaglutide in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, CagriSema or Semaglutide?

CagriSema is currently investigational (in trials) and Semaglutide is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

GLP-1 & Metabolic · Comparison

CagriSema vs Semaglutide

A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CagriSema

Investigational (in trials)

CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study.

Full profile

Semaglutide

FDA-approved

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It is FDA-approved under the brand names Ozempic (diabetes) and Wegovy (weight loss) and has become one of the most widely discussed peptides in mainstream health conversations.

Full profile

	CagriSema	Semaglutide
Category	GLP-1 & Metabolic	GLP-1 & Metabolic
Also known as	Cagrilintide + Semaglutide, AM833 + semaglutide, amylin/GLP-1 combination	Ozempic, Wegovy, Rybelsus, GLP-1 agonist
Evidence	Investigational (in trials)	FDA-approved
Dosing range	0.25mg–2.4mg mg, once weekly subcutaneous (each component 2.4mg at target)	0.25mg–2.4mg mg, once weekly (injectable); once daily (oral Rybelsus)
Administration	Subcutaneous injection (weekly)	Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus)
Key side effects	Nausea (most common, dose-dependent), Vomiting, Diarrhea or constipation, Decreased appetite	Nausea (very common, especially during dose escalation), Vomiting, Diarrhea or constipation, Reduced appetite (intended effect)
Cited sources	2 references	4 references

Key differences

Evidence level differs: CagriSema is investigational (in trials), while Semaglutide is fda-approved.
Administration: CagriSema — Subcutaneous injection (weekly); Semaglutide — Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus).
Frequency: CagriSema is typically once weekly subcutaneous (each component 2.4mg at target); Semaglutide is once weekly (injectable); once daily (oral Rybelsus).
Research depth: this profile cites 2 sources for CagriSema vs 4 for Semaglutide.

How each works

CagriSema

CagriSema combines amylin-receptor agonism (cagrilintide — satiety and gastric emptying via the area postrema/hypothalamus) with GLP-1 agonism (semaglutide), two non-overlapping appetite mechanisms. The REDEFINE 1 and 2 trials supported a December 2025 FDA filing for weight management. However, the open-label REDEFINE-4 head-to-head trial showed 23.0% weight loss vs 25.5% for tirzepatide 15 mg, missing its primary non-inferiority endpoint. An FDA decision is expected in late 2026.

Semaglutide

Semaglutide has robust clinical trial data — including the STEP and SUSTAIN trial series — demonstrating significant weight loss (15–20% body weight), glycemic control, and cardiovascular risk reduction. It works by mimicking the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, and reducing appetite via central nervous system signaling.

Read the full CagriSema profile Read the full Semaglutide profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.